Fidelity SPDR Advertisement
Home > Boards > US OTC > Biotechs >

NanoLogix, Inc. (NNLX)

Add NNLX Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator capitalismforever, shabby47, Emerald Isle
Search This Board:
Last Post: 12/15/2014 10:10:50 AM - Followers: 134 - Board type: Free - Posts Today: 0

Nanologix is a biotechnology company focused on rapid medical diagnostics. 
NanoLogix technology is used to design and market diagnostic test kits for use in early detection of bacteria and other microorganisms present in infectious and noninfectious human diseases, the environment, industrial and manufacturing settings, veterinary medicine, and research and testing laboratories. 
NanoLogix began 20 years ago under the name Infectech. The company has been issued 33 patents applicable in the areas of applied microbiology, soil microbiology, medical diagnostics, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, antibiotic sensitivity, stem-cell research, and hydrogen generation through use of bioreactors.
In 2007 the focus of the company evolved from pure Research and Development to capitalizing on the company's intellectual property through a transition to production of BNP™ and BNF™ Ultra-Fast diagnostic test kits and their marketing.     
Rapid Diagnostics and the BNP™

NanoLogix brings new velocity to the cutting edge field called "rapid diagnostics."  For that reason the company chose the term "Ultra-Fast" diagnostics for the BNP™. Other early detection devices in development at NanoLogix will bear the same designation.
Reduced testing time can save lives and money.

Nanologix Technology

NanoLogix technology provides live-cell rapid detection and identification dramatically faster than Flow Cytometry and traditional Petri culture methods. Additionally, in contrast to other fast methods such as Polymerase Chain Reaction (PCR), Nanologix technology does not require large investments in equipment or personnel training.

Based on advancements in Petri dish technology, the company's  Quick Test Kits, BioNanoPore (BNP™), and BioNanoFilter (BNF™) technologies are simple, easy to use and portable. The company states that the kits provide a more accurate, cost-effective alternative to PCR and Flow Cytometry.

Test Results  --  PARTIALLY UPDATED AS OF 01/31/2013-- FOR REFERENCE ONLY --

NanoLogix technology returns live-cell test results dramatically faster than Flow Cytometry and traditional Petri culture methods. Additionally, the technology is stated to be easy-to-use and does not require large investments in equipment or personnel training.



Comparison of BNP™ and BNF™ with traditional Petri dish technology.




          Microorganism BNP BNF

Traditional Time Range for Observance of Culture

Tuberculosis Mycobacterium tuberculosis
(ATCC 35801)

5 days* 1.5 hours*
21+ days
Vibrio cholerae (Cholera) 7 hours* <1 hour* 24+ hours
Yersinia pestis Yersinia pestis (bubonic plague) 24 hours* <1 hour* 48 hours
Bacillus anthracis Bacillus anthracis, (Anthrax) 6 hours* <1 hour* 24 hours
Group B Strep Group B Streptococcus (GBS) 4 hours <1 hour* 48 - 72 hours
Staphylococcus aureus Methicillin-resistant Staphylococcus aureus (MRSA) in process 6 hours* 18 - 24 hours
Burkholderia pseudomallei Burkholderia pseudomallei in process <1 hour* 18 - 24 hours
Brucella melitensis Brucella melitensis Brucella melitensis in process <1 hour* 18 - 24 hours
Escherichia coli Escherichia coli (E.coli) 0.5 hour 4 hours 18 - 24 hours
Salmonella Salmonella spp 0.5 hour 1 hour* 24 hours
Listeria ssp Listeria spp 5 hours in process 18 - 24 hours
Pseudomonas aeruginosa Pseudomonas aeruginosa 3 hours 5 hours 18 - 24 hours
Klebsiella pneumoniae Klebsiella pneumoniae 0.5 hour in process 24 hours
Endobacter cloacae Enterobacter cloacae 30 minutes 5 hours 24 hours
cryptosporidium Cryptosporidium in process <4 hours 14+ days
Streptococcus pyogenes 1 hour in process 18 - 24 hours
Gonorrhea pic Gonorrhea - <1 hour* 48 - 72 hours
cdiff pic Clostridium difficile  (C. Diff.) 4 hours* - 48 - 72 hours
  Assorted Yeasts  and Molds 12 -16 hours in process 48 - 72 hours

"NanoLogix Average" days/hours are based upon results achieved by NNLX through internal testing or results reported from independent third party tests. Detection time depends upon environmental conditions, sample quality, microorganism growth rates, nutrient concentrations, and many other factors. Actual results may vary.

 *External third-party results


The benefits of Ultra-Fast diagnostics are far-reaching:
·  Ultra-Fast diagnostics allow researchers in the lab to test for potentially pathogenic agents faster and develop effective countermeasures more rapidly and economically. This quality presents exciting opportunities in the pharmaceutical design process. 
  Can begin more effective drug treatment when an infectious disease is identified at an early stage. The spread of infectious disease may be reduced by earlier intervention. 
·In combat theaters and homeland security settings, the presence of specific pathogens can be detected closer to the epicenter of release. Site decontamination teams can identify surface samples closer to real time, potentially aiding the field process. 
 Industrial production - of food, beverage, drugs, or beauty products - can be paralyzed by microbial contamination.  The ripple effect may include expensive recalls, bad publicity, and government mandated "microbiology holds" that delay the replacement of product.  Ultra-Fast diagnostics can help minimize the impact by limiting the spread of spoiled product.
The BNP™ Ultra-Fast test kit is the first of NanoLogix's inventions to go to market. 
Advantages of BNP™
There are three main approaches to detection of microbes.  The conventional approach uses the Petri dish to culture samples in agar.  In general, this requires at least an 18 - 24 hour wait, in many instances much longer.
More recently, two other approaches have developed.  One is PCR (Polymerase Chain Reaction), and the other Flow Cytometry.
PCR technology detects the DNA of a cell.  Its shortcoming is the inability to distinguish between a live or dead cell.  It cannot be used for the determination of the actual threat posed by a potentially dangerous microorganism. The process utilizes complicated opto-electronics computerized instrumentation, with an equipment acquisition price of approximately $100,000.
Until NanoLogix's BNP™ appeared, Flow Cytomery was the standard for "fast" detection.  Though it can analyze one cell or particle in 1/10,000 of a second, it needs 18 hours (vs. 24 hours with the standard Petri dish) to provide accurate results.  It is also expensive and requires special equipment and technicians.
With the advent of BNP's™ technology, rapid diagnostics has just gained an important new tool.  
Based on Petri dish technology, the BNP™ provides a cheap, ultra-fast result in as little as one-third the time of the Flow Cytometry method, and one-quarter the time of the traditional Petri dish method.  It distinguishes between live and dead cells (a crucial requirement in identifying dangerous microbes.)  The technology is simple, easy to use, and portable.  It provides viewable cultures for evaluation far faster than any other method in use.
The BNP™
The BioNanoPore (BNP™) kit employs a membrane that is extremely thin, translucent, water permeable, and capable of working with organic and non-organic molecules and proteins. The membrane is non-permeable to cell structures, non-toxic for cells, hydrophilic, and non-fluorescent.  The BNP™ membrane is covered by a thin layer of solid nutrient media and can be used with nutrient agars of the type widely used in microbiological diagnostics.


How the BioNanoPore (BNP™) Membrane Works


Simple to use:

Inoculate microorganisms on BNP™ Petri-based isolator plate 1.

After a rapid incubation period, generally a fraction of traditional incubation times, transfer the BNP™ membrane to BNP™ staining plate 2.

Within minutes, micro-colonies are visible on staining plate.

The volume of Petri dishes used for traditional tests is millions per day worldwide. NanoLogix anticipates that the BNP™ Ultra-Fast technology will capture a portion of that market. 
According to Industrial Microbiology Market Review, worldwide industrial microbiology testing is undergoing tremendous growth. The same growth pattern is anticipated in the medical microbiological diagnostics market.
NanoLogix's potential customers are numerous and varied. They include microbiological laboratories in the industrial, medical, environmental, governmental (federal, state and local) sectors, research and development facilities, and educational institutions. 
NanoLogix's research and development continues on other diagnostic technology. The company's BNC™ technology utilizes a small disk with millions of nano-channels to trap microorganisms for analysis. Initial production of BNC™ kits will begin in late 2009. Extensive laboratory and field research was done from 2005-2008 on extraction of hydrogen gas from organic waste, with the data archived for potential future use.


The patent information link:



Estimated Market Cap

  • $14,249,954 as of Jun 3, 2009


Outstanding Shares

         As of 1 April 2013, the company has 122,679,679 shares outstanding

         Authorized Shares         200,000,000 as of Dec 31, 2008

Number of Share Holders of Record

  • Over 3,000 shareholders as of early 2012.

        Float of 73,425,356 shares as of Dec 31, 2008



Price Quote:

( 1 month daily, 3 month daily, 1 year weekly)




Corporate Headquarters

NanoLogix, Inc.

843 North Main Street
Hubbard, OH 44425 USA
330-534-0800 main line
330-534-0826 fax


Web site questions:



NANOLOGIX IS A BIOTECHNOLOGY COMPANY specializing in rapid diagnostics tools for biodefense, medical, environmental, and industrial uses.

The primary focus of NanoLogix is rapid detection of bacteria and other microorganisms.

The BNP™ ultra-fast test kit sets a new standard for accurate, high-speed diagnostics. With results two to four times faster than traditional Petri dish methods, NanoLogix technology represents a revolutionary next step in disease identification. 

Uses for NanoLogix's very-rapid diagnostics include biodefense, human and veterinary medicine, processing and safety of food, cosmetics and drugs, research and development, and industrial and environmental testing. Rapid detection of microorganisms is an annual multi-billion dollar market.

NanoLogix has been issued 33 patents in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, antibiotic sensitivity, stem-cell research, and bioreactor-based hydrogen generation. 



  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
NNLX News: NanoLogix Technology Being Configured For Rapid Ebola Virus Detection 10/14/2014 09:30:00 AM
NNLX News: NanoLogix Technology Cited In UNITAID Annual Report On TB, Through The World Health Organization 09/29/2014 09:30:00 AM
NNLX News: NanoLogix to Exhibit at BioOhio Exposition, Receives European Allowance for BNP Patent 07/08/2014 12:05:00 AM
#8230  Sticky Note EVERYONE get your posts back on-topic. The IH Geek [Dave] 11/21/13 03:54:06 PM
#9049   I made a breakdown of all the different shabby47 12/15/14 10:10:50 AM
#9048   I agree 100% with you. In addition, I capitalismforever 12/12/14 07:23:19 PM
#9047   The value of a company, what I call tedturnernot 12/12/14 06:03:39 PM
#9045   So you admit that you don't inder the shabby47 12/11/14 05:21:45 PM
#9044   "A logical person would also put some weight capitalismforever 12/11/14 04:53:17 PM
#9043   Any "logical person" would realize exactly what is shabby47 12/11/14 03:01:41 PM
#9042   "I did not say anything about the value capitalismforever 12/11/14 02:30:51 PM
#9041   I did not say anything about the value shabby47 12/11/14 02:24:40 PM
#9040   The "educated investors" comment wasn't a barb. It capitalismforever 12/11/14 01:54:26 PM
#9039   Easy there. It is just an observation about shabby47 12/11/14 01:25:55 PM
#9038   I think it's just another example of Mr. capitalismforever 12/11/14 11:49:51 AM
#9037   It looks like the bid is actually moving shabby47 12/11/14 10:59:26 AM
#9036   This would have happened in Q4 2013. Can capitalismforever 12/10/14 04:36:15 PM
#9035   I don't know who they were attempting to capitalismforever 12/10/14 01:35:04 PM
#9034   That doesn't negate my comment. capitalismforever 12/10/14 01:33:05 PM
#9033   That's an interesting tool. I believe at ttboy 12/10/14 01:31:55 PM
#9032   You should go to PR Newswire, BusinessWire, MarketWired, Emerald Isle 12/10/14 01:27:24 PM
#9031   I corrected the date in my previous post. capitalismforever 12/10/14 01:17:57 PM
#9030   Please post this link from 7 years ago. ttboy 12/10/14 01:15:08 PM
#9029   One great feature the internet has is called capitalismforever 12/10/14 01:08:43 PM
#9028   "All you have provided are the various places capitalismforever 12/10/14 12:56:50 PM
#9027   In their August 2012 press release Nanologix stated Emerald Isle 12/10/14 12:55:15 PM
#9026   "You are a moderator of this board. What ttboy 12/10/14 12:49:24 PM
#9025   Now that is absolutely wrong relative to what Emerald Isle 12/10/14 12:45:44 PM
#9024   "Possibly, but I doubt it. If you had, capitalismforever 12/10/14 12:35:46 PM
#9023   "Much longer than you I'm certain." ttboy 12/10/14 12:29:54 PM
#9022   "I don't know your definition of several." capitalismforever 12/10/14 12:21:51 PM
#9021   "I could not find any further comment from capitalismforever 12/10/14 12:13:12 PM
#9020   "They've had an order page on their website ttboy 12/10/14 12:07:30 PM
#9019   "Again, the point I'm trying to make is capitalismforever 12/10/14 11:54:57 AM
#9018   The actual January 27, 2014 quote from a Emerald Isle 12/10/14 11:46:28 AM
#9017   "Most biotechnology companies have high R&D expenses. There ttboy 12/10/14 11:42:23 AM
#9016   Apologies. That was the bnp patent. The n-assay shabby47 12/10/14 11:18:51 AM
#9015   "I see that you're stuck on Q1 revenue." capitalismforever 12/10/14 11:13:47 AM
#9014   Most biotechnology companies have high R&D expenses. There capitalismforever 12/10/14 11:02:00 AM
#9013   "This is the bnp patent that uses aptamers ttboy 12/10/14 11:00:02 AM
#9012   Actually, in all your sarcasm, you've missed the ttboy 12/10/14 10:56:12 AM
#9011   Also, with regard to the n-assay patent, this shabby47 12/10/14 10:50:50 AM
#9010   "After nearly 8 years, $18,550 in quarterly revenue ttboy 12/10/14 10:45:47 AM
#9009   "The EU patient, for example, expires in 14 capitalismforever 12/10/14 10:41:14 AM
#9008   This is correct. And their most important application shabby47 12/10/14 10:33:12 AM
#9007   The EU patient, for example, expires in 14 ttboy 12/10/14 10:23:58 AM
#9006   I believe if any increase happens, it will capitalismforever 12/10/14 08:39:34 AM
#9005   "This is what YOU said on another MB. capitalismforever 12/10/14 08:36:35 AM
#9004   Maybe you've missed this. You honestly believe ttboy 12/10/14 08:15:40 AM
#9003   You stated that shabby47 12/10/14 07:18:24 AM
#9002   "A rough analysis of the economic potential of capitalismforever 12/09/14 11:32:52 PM
#9001   "That is one man's OPINION which in my capitalismforever 12/09/14 08:51:28 PM
#9000   Please explain where I get what information specifically? capitalismforever 12/09/14 08:45:43 PM
#8999   Please explain where you get this information. Otherwise shabby47 12/09/14 08:01:04 PM